Growth Metrics

Unicycive Therapeutics (UNCY) Preferred Stock Liabilities (2023 - 2024)

Unicycive Therapeutics filings provide 2 years of Preferred Stock Liabilities readings, the most recent being $46.2 million for Q2 2024.